---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-020847"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T01:57:49.745825+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment

## Summary
- All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.
- Ratification of Weinberg & Company as FY 2025 auditor passed: 1.79M for, 59K against.
- Non-binding advisory vote on executive compensation approved: 1.17M for, 20K against.
- Approved issuance of up to 19.99% of outstanding common stock related to May 2025 purchase agreements and convertible preferred.
- Amendment No. 1 to 2022 Omnibus Incentive Plan, increasing shares by 583,334, approved: 1.15M for, 35K against.

## SEC filing metadata
- accession: 0001641172-25-020847
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000164117225020847/0001641172-25-020847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000164117225020847/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-020847
- JSON: https://secwatch.observer/filing/0001641172-25-020847.json
- Plain text: https://secwatch.observer/filing/0001641172-25-020847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.